Cargando…

Phase-transitional Fe(3)O(4)/perfluorohexane Microspheres for Magnetic Droplet Vaporization

Activating droplets vaporization has become an attractive strategy for ultrasound imaging and physical therapy due to the significant increase in ultrasound backscatter signals and its ability to physically damage the tumor cells. However, the current two types of transitional droplets named after t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ronghui, Zhou, Yang, Zhang, Ping, Chen, Yu, Gao, Wei, Xu, Jinshun, Chen, Hangrong, Cai, Xiaojun, Zhang, Kun, Li, Pan, Wang, Zhigang, Hu, Bing, Ying, Tao, Zheng, Yuanyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381248/
https://www.ncbi.nlm.nih.gov/pubmed/28382158
http://dx.doi.org/10.7150/thno.17251
Descripción
Sumario:Activating droplets vaporization has become an attractive strategy for ultrasound imaging and physical therapy due to the significant increase in ultrasound backscatter signals and its ability to physically damage the tumor cells. However, the current two types of transitional droplets named after their activation methods have their respective limitations. To circumvent the limitations of these activation methods, here we report the concept of magnetic droplet vaporization (MDV) for stimuli-responsive cancer theranostics by a magnetic-responsive phase-transitional agent. This magnetic-sensitive phase-transitional agent—perfluorohexane (PFH)-loaded porous magnetic microspheres (PFH-PMMs), with high magnetic-thermal energy-transfer capability, could quickly respond to external alternating current (AC) magnetic fields to produce thermal energy and trigger the vaporization of the liquid PFH. We systematically demonstrated MDV both in vitro and in vivo. This novel trigger method with deep penetration can penetrate the air-filled viscera and trigger the vaporization of the phase-transitional agent without the need of pre-focusing lesion. This unique MDV strategy is expected to substantially broaden the biomedical applications of nanotechnology and promote the clinical treatment of tumors that are not responsive to chemical therapies.